- Trials with a EudraCT protocol (983)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
983 result(s) found for: Squamous Cell Carcinoma.
Displaying page 1 of 50.
EudraCT Number: 2009-015237-76 | Sponsor Protocol Number: LUC 09-002 | Start Date*: 2010-04-26 | ||||||||||||||||
Sponsor Name:Centre du Cancer des Cliniques Universitaires Saint-Luc | ||||||||||||||||||
Full Title: An open label multicentric phase II study of Panitumumab (Vectibix®) in cutaneous squamous cell carcinoma (SCC) | ||||||||||||||||||
Medical condition: Cutaneous Squamous Cell Carcinoma (SCC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-000781-23 | Sponsor Protocol Number: GEN207 | Start Date*: 2008-06-09 | ||||||||||||||||
Sponsor Name:Genmab A/S | ||||||||||||||||||
Full Title: An Open-label, International, Multi-Center, Phase I/II, Dose-escalation Trial Investigating the Safety of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Combination wi... | ||||||||||||||||||
Medical condition: Stage III, IVa or IVb Locally Advanced Squamous Cell Carcinoma of the Head and Neck Ineligible for Platinum based Chemotherapy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) FR (Prematurely Ended) BE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-003495-31 | Sponsor Protocol Number: CCLL442X2201 | Start Date*: 2017-12-14 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized, Investigator-and patient-blind, placebo-controlled, parallel group first in human and proof of concept study to evaluate the safety, tolerability, and efficacy of CLL442 in patients w... | |||||||||||||
Medical condition: Cutaneous Squamous Cell Carcinoma in situ (SCCis) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004603-35 | Sponsor Protocol Number: REACH | Start Date*: 2009-04-28 | |||||||||||||||||||||
Sponsor Name:University of Heidelberg | |||||||||||||||||||||||
Full Title: Radiotherapy (IMRT), Erbitux And Chemotherapy For Unresectable Carcinomas Of Head and Neck. REACH-Study | |||||||||||||||||||||||
Medical condition: Histologically confirmed locally advanced (stage III or IV), non-metastatic squamous cell carcinoma of oro-, hypopharynx or larynx (T2-4, NX, M0). | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-001623-18 | Sponsor Protocol Number: EGF102988 | Start Date*: 2006-12-07 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib or P... | |||||||||||||
Medical condition: Resected Squamous Cell Carcinoma of the Head and Neck | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) IE (Completed) GR (Completed) AT (Completed) SK (Completed) GB (Completed) DE (Completed) CZ (Completed) PT (Prematurely Ended) EE (Completed) HU (Completed) IT (Completed) LV (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003833-24 | Sponsor Protocol Number: AGMT_HNO_PN | Start Date*: 2016-06-30 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:AGMT – Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Randomized phase III study: Supplemental parenteral nutrition for patients with locally advanced inoperable tumors of the head and neck, receiving definitive radiotherapy with Cetuximab or Cisplatin | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Locally advanced inoperable tumors of the head and neck under definitive radiotherapy with Cetuximab or Cisplatin | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: AT (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-007034-18 | Sponsor Protocol Number: DCC | Start Date*: 2009-01-26 | ||||||||||||||||
Sponsor Name:Charité Universitätsmedizin Berlin - CVK | ||||||||||||||||||
Full Title: Phase II-Studie zur Erfassung der Effektivität einer wöchentlich verabreichten Docetaxel-Carboplatin/Cisplatin-Cetuximab-Kombination (DCC) bei fortgeschrittenen Plattenepithelkarzinomen des Orophar... | ||||||||||||||||||
Medical condition: patients with advanced squamaous cell carcinom on oropharynx or oral cavity | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-001951-20 | Sponsor Protocol Number: UCL/06/053 | Start Date*: 2008-03-12 | ||||||||||||||||
Sponsor Name:University College London | ||||||||||||||||||
Full Title: A phase I and randomised phase II study of Docetaxel and RAD001 (Everolimus) in advanced/recurrent or metastatic squamous cell carcinoma of the head and neck | ||||||||||||||||||
Medical condition: Locally advanced or metastatic squamous cell carcinoma of the head and neck | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-003622-86 | Sponsor Protocol Number: CA209-141 | Start Date*: 2014-06-05 | |||||||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||||||||||||
Full Title: An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN) | |||||||||||||||||||||||
Medical condition: Squamous cell carcinoma of the head and neck | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) GB (Completed) ES (Completed) DE (Completed) NL (Completed) FR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-003007-35 | Sponsor Protocol Number: R2810-ONC-1901 | Start Date*: 2020-02-04 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II to IV (M0) Cutaneous Squamous Cell Carcinoma (CSCC) | |||||||||||||
Medical condition: Stage II to IV cutaneous squamous cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019071-29 | Sponsor Protocol Number: 006/09 | Start Date*: 2010-07-26 | |||||||||||
Sponsor Name:BioVex, Inc. | |||||||||||||
Full Title: A Phase 3 Randomized Trial of Concurrent Cisplatin And Radiotherapy With or Without OncoVEXGM-CSF in Previously Untreated Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck | |||||||||||||
Medical condition: Locally Advanced Squamous Cell Carcinoma of the Head and Neck | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005702-39 | Sponsor Protocol Number: O08-1 | Start Date*: 2009-03-16 | |||||||||||
Sponsor Name:GERCOR | |||||||||||||
Full Title: Phase I/II study of Induction Chemotherapy with weekly RAD001, Carboplatine and Paclitaxel in Unresectable or Inoperable Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) | |||||||||||||
Medical condition: Unresectable or Inoperable locally advanced head and neck squamous cell carcinoma without any prior chemotherapy or radiotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003415-26 | Sponsor Protocol Number: 2021-003415-26 | Start Date*: 2022-01-07 | ||||||||||||||||||||||||||
Sponsor Name:Department of Oncology, Rigshospitalet | ||||||||||||||||||||||||||||
Full Title: HERES trial: Trastuzumab and standard treatment with chemo- and immunotherapy as first line treatment for HER2 positive esophageal squamous cell carcinoma patients | ||||||||||||||||||||||||||||
Medical condition: HER2 positive Esophageal Squamous Cell Carcinoma | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DK (Trial now transitioned) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001506-29 | Sponsor Protocol Number: ML 18729 | Start Date*: 2005-10-10 | |||||||||||
Sponsor Name:Group of Clinical Investigation in Radiotherapy Oncology (GICOR) | |||||||||||||
Full Title: PHASE I/II TRIAL OF ERLOTINIB, RADIATIONTHERAPY, AND CISPLATIN IN PATIENTS WITH COMPLETE RESECTED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK Ensayo Fase I/II de Erlotinib en combinación con radio... | |||||||||||||
Medical condition: PATIENTS WITH COMPLETE RESECTED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003484-23 | Sponsor Protocol Number: Paccis-RCT_2005 | Start Date*: 2010-04-14 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Universitätsklinikum Erlangen, Strahlenklinik insoweit handelnd für den Freistaat Bayern | |||||||||||||||||||||||||||||||||||||||||||
Full Title: Randomised phase-III-trial of simultaneous radiochemotherapy (RCT) of locally advanced head and neck cancer in the stages III and IV A-B: Comparing dose reduced RCT (63.6 Gy) with Paclitaxel/Cispla... | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Head and Neck cancer, Stage III-IV A-B | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-001016-21 | Sponsor Protocol Number: AGMT_ECa | Start Date*: 2008-08-28 | |||||||||||
Sponsor Name:Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH | |||||||||||||
Full Title: Multizentrische Phase II Studie: Induktionschemotherapie und Chemoradiotherapie jeweils in Kombination mit Cetuximab bei Patienten mit nicht-metastasiertem Ösophaguskarzinom | |||||||||||||
Medical condition: Unbehandeltes, histologisch gesichertes, nicht-metastasiertes Ösophaguskarzinom (Plattenepithelkarzinom) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001354-41 | Sponsor Protocol Number: UCLONCO08-001 | Start Date*: 2008-04-11 | ||||||||||||||||||||||||||
Sponsor Name:Cliniques Universitaires St Luc, Centre du Cancer | ||||||||||||||||||||||||||||
Full Title: Neoadjuvant cetuximab monotherapy followed by surgery in squamous cell carcinoma of head and neck: phase I/II study | ||||||||||||||||||||||||||||
Medical condition: patients with squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx newly diagnosed and eligible for surgery. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-000777-21 | Sponsor Protocol Number: OncoVEXGM-CSF/004/04 | Start Date*: 2005-07-06 | |||||||||||
Sponsor Name:BioVex Ltd | |||||||||||||
Full Title: AN EXPLORATORY STUDY OF THE SAFETY AND BIOLOGICAL ACTIVITY OF ONCOVEXGM-CSF IN COMBINATION WITH RADIOTHERAPY AND CISPLATIN IN THE TREATMENT OF LOCALLY ADVANCED EPITHELIAL CANCER OF THE HEAD AND NECK | |||||||||||||
Medical condition: Locally advanced epithelial cancer of the head and neck. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002116-25 | Sponsor Protocol Number: O 07-1 | Start Date*: 2008-02-25 | |||||||||||
Sponsor Name:GERCOR | |||||||||||||
Full Title: chimiothérapie d'induction par Erbitux-Taxotère-Cisplatine-5FU (ETPF) dans les carcinomes épidermoides de l'oropharynx de stade III-IV opérables | |||||||||||||
Medical condition: carcinome épidermoïde de l’oropharynx de stade III (T3 ou T1T2N1N2M0) ou IV non métastatiques (T4 ou TNM0) selon la classification de l’UICC 2002 , considérés comme résécables d’emblée | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000533-40 | Sponsor Protocol Number: CIBI308A301 | Start Date*: 2020-10-05 | |||||||||||||||||||||
Sponsor Name:Innovent Biologics (Suzhou) Co., Ltd. | |||||||||||||||||||||||
Full Title: A Multicenter, Double-Blind, Randomized Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectab... | |||||||||||||||||||||||
Medical condition: Esophageal Squamous Cell Carcinoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) BE (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
